Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Ardelyx, Inc.NASDAQ: ARDX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 94.9%

Gross margin was 94.9% in Q1 FY2026, up 12.3 pp from a year earlier. On a trailing-twelve-month basis it was 91.9%, up 7.7 pp year over year. Over 3 fiscal years it narrowed by 2.6 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
94.9%+4.3 pp QoQ
Last fiscal yearDec 2025
89.5%+4.7 pp YoY
LTMMar 2026
91.9%+7.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+12.3 pp——
1 year+4.7 pp——
3 years-2.6 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
89.5%
Year-over-year change
+4.7pp

Gross Margin vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 gross margin of 91.9% is the 2nd highest of the 4 companies compared; the peer median is 81.6%.
  • Its year-over-year change of +7.7 pp is the 2nd highest of 4, against a peer median of +0.6 pp.
  • Over three fiscal years its change of -2.6 pp compares with a peer median of -3.4 pp.
ARDX Competitors Peer median
Gross Margin for ARDX and competitors
Company Period LTM level YoY 3-year change
MAZEMaze Therapeutics, Inc.LTM Mar 202692.0% -8.0 pp—
ARDXArdelyx, Inc.LTM Mar 202691.9% +7.7 pp-2.6 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 202681.6% +0.6 pp+2.2 pp
AKBAAkebia Therapeutics, Inc.LTM Mar 202680.9% +8.2 pp-9.0 pp
DMACDiaMedica Therapeutics Inc.FY2025— ——
Peer median (excluding ARDX) 81.6%+0.6 pp-3.4 pp

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.1M52.16M124.46M333.62M407.32M
Cost of Revenue1M4.12M17.8M50.56M42.6M
Gross Profit9.1M48.04M106.66M283.06M364.72M
Gross Margin90.1%92.1%85.7%84.8%89.5%
Research & Development91.14M35.2M35.54M52.32M68.47M
Selling, General & Admin72.3M76.6M134.4M258.69M337.23M
Operating Expenses163.44M111.8M169.94M311.01M405.7M
Depreciation & Amortization2.81M1.14M1.29M2.06M3.06M
EBITDA(150.85M)(60.98M)(55.35M)(16.71M)(29.17M)
EBITDA Margin-1494.0%-116.9%-44.5%-5.0%-7.2%
Operating Income(154.35M)(63.76M)(63.28M)(27.95M)(40.98M)
Operating Margin-1528.6%-122.2%-50.8%-8.4%-10.1%
Interest Income00000
Interest Expense4.5M5.07M8.87M20.09M28.4M
Other Income / Expenses(3.82M)(3.44M)(2.24M)(10.92M)(19.65M)
Income Before Tax(158.16M)(67.2M)(65.52M)(38.87M)(60.63M)
Pre-Tax Margin-1566.4%-128.8%-52.6%-11.7%-14.9%
Income Tax Expense4K8K547K266K969K
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Net Margin-1566.5%-128.9%-53.1%-11.7%-15.1%
EPS (Basic)(1.52)(0.42)(0.30)(0.17)(0.26)
EPS (Diluted)(1.52)(0.42)(0.30)(0.17)(0.26)
Weighted Avg Shares104.21M158.69M219.33M235.23M241.03M
Weighted Avg Shares (Diluted)104.21M158.69M219.33M235.23M241.03M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.